SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Myriad Genetics, Inc. (MYGN) -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (1729)11/28/2005 1:42:08 PM
From: tuck  Read Replies (1) | Respond to of 2355
 
Hi, Harry,

Good of you to drop by. Pretty much agree with your assessment of Flurizan. I think the market does, too. If only management did (either by dropping it or partnering (but good luck attracting a partner with these results)). Anyhow, I have a small position via sold puts. The reason for that is a) the predictive medicine business that you alluded to, and b) the early stage oncology programs that you did not allude to. There's also the viral budding program, but I need to check this against PA-457, which is farther along, and comparable (I think).

Cheers, Tuck



To: NeuroInvestment who wrote (1729)11/28/2005 3:37:40 PM
From: rkrw  Read Replies (1) | Respond to of 2355
 
Harry, I'm very curious about Voyager. Are they con men or is there substance behind all the hype?

I've never had much interest in flurizan. The predictive medicine business is probably worth close to the market cap and they seem to be putting together a deep oncology pipeline.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News